Pharmaceutical titan Merck & Co. Inc. has announced a landmark $10 billion acquisition of Verona Pharma plc, underscoring its ...

US Foods Holding stock hit an all-time high Friday on a report that the firm was mulling an acquisition of Performance Food ...

Investment firms in Boston and New York could see the biggest gains from the sale of a Raleigh drugmaker. Raleigh pharma ...

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...

Freshfields and Latham & Watkins are advising on the latest pharmaceutical mega-deal as U.S. pharmaceutical group Merck snaps up lung disease-focused biotech Verona Pharma. Merck, which is known as ...

Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Merck & Company today and set a price target of $82.00. The company’s shares closed yesterday at $81.37. Don’t M ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster product ...

The U.S. drug giant said that Verona’s Ohtuvayre, which treats chronic obstructive pulmonary disease, will strengthen its lineup of cardiovascular treatments.

Merck & Co. Inc. has strengthened its cardiopulmonary pipeline with its $10 billion acquisition of London-based-Verona Pharma plc. The deal brings Merck Ohtuvayre (ensifentrine) for chronic ...

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc.

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...